PBH · XBRL financial data

Prestige Consumer Healthcare financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PBH's year ends in late March)

In millions of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Revenue from contracts with customers	286	283	277*	267	284	290	297*	250	274	283	282*	266
Cost of revenue	126	125	125*	121	126	129	127*	109	123	126	135*	130
Gross profit	160	158	152*	146	157	161	170*	140	152	157	146*	136
General and administrative	26	26	26*	29	26	26	27*	28	28	30	30*	43
Total operating expenses	72	71	70*	74	73	69	82*	69	72	75	71*	84
Operating income (loss)	88	87	82*	72	84	92	88*	72	80	82	75*	53
Interest expense	18	17	(47)*	13	12	11	(35)*	—	—	—	—	—
Other income (expense)	(0)	(1)	0*	(0)	(0)	(0)	(4)*	0	(1)	(10)	1*	(0)
Income tax expense (benefit)	17	17	18*	9	17	19	24*	14	27	15	11*	9
Net income (loss)	54	53	49*	49	54	61	50*	47	42	47	54*	29
Earnings per share, basic USD per share	1.08	1.07	0.99*	0.98	1.10	1.23	1.01*	0.96	0.86	0.98	1.14*	0.61
Earnings per share, diluted USD per share	1.07	1.06	0.98*	0.98	1.09	1.22	1.00*	0.95	0.86	0.97	1.13*	0.61
Weighted average shares, basic millions of shares	50	50	50*	50	50	50	50*	49	49	48	47*	47
Weighted average shares, diluted millions of shares	50	50	50*	50	50	50	50*	50	49	48	48*	48

Fiscal quarters (PBH's year ends in late March)

In millions of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Cash and cash equivalents	60	64	46	34	52	51	98	140	119	62	64	89
Accounts receivable	158	174	177	172	164	167	194	168	199	190	192	187
Inventory	161	149	139	152	156	152	148	153	159	164	159	190
Prepaid and other current assets	8	7	13	11	9	8	8	19	20	17	17	30
Total current assets	388	394	375	369	381	377	448	481	497	433	431	497
Property and equipment, net	71	70	77	75	75	74	75	74	73	128	122	117
Right-of-use asset	12	11	11	10	9	30	28	27	25	24	28	26
Goodwill	527	528	528	528	529	527	527	528	528	581	581	651
Total assets	3,333	3,340	3,318	3,308	3,317	3,329	3,402	3,432	3,442	3,495	3,494	4,569
Accounts payable	44	39	39	40	31	20	19	22	42	43	23	37
Current portion of long-term debt	—	—	—	—	—	—	—	—	—	—	0	10
Total current liabilities	130	127	117	114	107	103	107	110	135	140	121	154
Long-term debt	1,275	1,210	1,126	1,100	1,060	1,000	—	—	—	—	994	2,007
Lease liability, non-current	7	6	8	7	7	24	23	21	20	18	21	19
Total liabilities	1,797	1,739	1,663	1,627	1,585	1,541	1,567	1,576	1,617	1,665	1,607	2,652
Retained earnings	1,239	1,292	1,341	1,390	1,445	1,506	1,556	1,603	1,645	1,692	1,746	1,775
Total stockholders' equity	1,536	1,601	1,655	1,681	1,732	1,788	1,835	1,855	1,825	1,829	1,888	1,917
Total liabilities and equity	3,333	3,340	3,318	3,308	3,317	3,329	3,402	3,432	3,442	3,495	3,494	4,569
Common shares outstanding (cover page) millions of shares	50	50	50	50	49	50	49	49	48	47	47	47

Fiscal quarters (PBH's year ends in late March)

In millions of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Net income (loss)	54	53	49*	49	54	61	50*	47	42	47	54*	29
Stock-based compensation	4*	2*	4*	3	2*	3*	3*	4	2*	3*	3*	4
Depreciation and amortization	8*	8*	8*	8	8*	7*	7*	8	8*	8*	8*	9
Net cash from operating activities	62*	71*	67*	55	70*	65*	62*	79	57*	78*	43*	71
Purchases of property and equipment	3*	2*	3*	1	2*	2*	3*	1	2*	3*	5*	4
Net cash from investing activities	(3)*	(4)*	(15)*	(2)	(2)*	(10)*	(3)*	(2)	(3)*	(129)*	(3)*	(1,064)
Share repurchases	0*	0*	0*	26	12*	2*	11*	35	75*	46*	1*	0
Proceeds from long-term debt	—	—	—	—	—	—	—	0	—	—	—	1,045
Net cash from financing activities	(54)*	(65)*	(68)*	(66)	(51)*	(54)*	(11)*	(36)	(75)*	(7)*	(38)*	1,018
Net change in cash	5*	4*	(17)*	(12)	17*	(1)*	47*	42	(20)*	(57)*	1*	25

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Prestige Consumer Healthcare	89	266	71	47.4M	—	Q1 FY27 10-QJun 30, 2026
Viking Therapeutics	678	0	(138)*	127.5M	7.6 quarters	Q3 FY26 10-QSep 30, 2026
Protagonist Therapeutics	420	213	219*	64.7M	—	Q2 FY26 10-QJun 30, 2026
Ultragenyx Pharmaceutical	125	214	(97)*	98.6M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Avidity Biosciences	383	0.9*	(170)*	155.1M	2.3 quarters	Q4 FY25 10-KDec 31, 2025
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026
Cytokinetics	255	29	(160)*	139.0M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Summit Therapeutics	419	not reported	(141)*	797.7M	4.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.